Wondfo Will Bring Bocartis Molecular Diagnostic Techniques to China
Tang Shihua
DATE:  Sep 03 2018
/ SOURCE:  Yicai
Wondfo Will Bring Bocartis Molecular Diagnostic Techniques to China Wondfo Will Bring Bocartis Molecular Diagnostic Techniques to China

(Yicai Global) Sept. 3 -- Guangzhou Wondfo Biotech will introduce the molecular diagnostic techniques the Belgian company Biocartis Group has developed to mainland China through its wholly-owned Hong Kong unit.

The affiliate, Wondfo Biotech HK, recently penned a cooperation agreement with Biocartis to set up a joint venture in Hong Kong with a registered capital of EUR14 million (USD16.25 million), with each to hold 50 percent of shares. It will introduce Biocartis' proprietary Idylla molecular diagnostic platform's techniques to mainland China, the diagnostic service provider based in Guangzhou, southern China said in an announcement today.

The JV will also sign a technology licensing agreement with Biocartis as a platform for business cooperation between it and Wondfo to localize, register, manufacture, and promote the Idylla techniques and cooperate in attendant diagnostics, per the announcement.

The company will seek to embark on further cooperation with channels, experts, pharmaceutical companies and other parties to improve and sustain profitability, the announcement stated.

Based in Mechelen, Belgium, Biocartis listed on the Brussels Stock Exchange in 2015. It currently sells 15 tumor gene tests and 2 infectious disease diagnostic products in more than 70 countries and regions around the world, the announcement indicated.

The Idylla molecular diagnostic system supports almost every type of biological specimen. It generates accurate and reliable results with many detection targets. The reagents remain stable for a long time at room temperature, which ensures better and more extensive benefits to doctors and patients from this molecular diagnosis technology, the announcement added.

Editor: Ben Armour

Follow Yicai Global on
Keywords:   Joint Venture,Hong Kong,Molecular Diagnostic Techniques,Cancer Diagnosis,Idylla,Biocartis Group,Belgium,Wondfo